Potential eligible costs fall under the FEMA Category B, Emergency Protective Measures expense category, including:
American Hospital Association (AHA) are tracking the coronavirus disease 2019 (COVID-19) situation daily, offering ongoing updates and the latest resources to the health care supply chain professionals. As the COVID-19 outbreak evolves, AHRMM is working with the AHA and other AHA professional membership groups (PMGs), as well as members, public officials, personal protective equipment (PPE) vendors, donors, suppliers, and association and health care leaders to help address the challenges of the COVID-19 response.
N95/N99 Form Fitting Respirators
Face masks with integrated shield
Powered Air Purifying Respirator, PAPRs
Alcohol Based Hand Rub
Ventilators with PEEP Functionality
UVT 3 mL with flocked flex minitip
Nasopharyngeal (NP) flocked swabs and viral transport media tubes (1-3 mL)
Roche MagNA Pure 96 DNA and Viral NA Small Volume Kits
Roche MagNA Pure 96 System Fluid and Tips
Roche MagNA Pure 96 External Lysis Buffer
Biomerieux NuciSENS EasyMAG extraction system and supplies
As a result of the disruption of hospitals, healthcare systems and physician groups caused by the coronavirus, the main concern and focus is on patients, their families, and employees during this tremendously difficult time.
During this process, it is necessary to get as much funding as possible to cover additional costs incurred by the extra time and effort put forth including the larger quantity of supplies being utilized. The recent passage of the Federal Stimulus Bill had three relief packages, the third of which is The Coronavirus Aid, Relief and Economic Security (CARES) Act, passed on March 25th. Under this package, healthcare organizations have the opportunity to submit their incremental costs to obtain relief funding. These are costs that are in addition to the normal operating costs that are either “COVID-19 related” or “COVID-19 induced”. For example, extra PPE supplies fall into the former and opening new units to cohort non-COVID-19 patients would fall into the latter category.
The good news is that substantial funding is available. However, governmental rules and requirements around this funding will require an extreme degree of specificity, documentation, organization, and comprehensiveness – in order to actually receive this relief funding. This is somewhat akin to clinical documentation. If organizations don’t record their expenditures with sufficient specificity and have the backup data to support the claims, they will not be paid the correct amount, the amount they deserve.